TABLE 1.

Demographic data of the participants enrolled in the study.

Gender	Risperidone (Percent)	Clozapine (Percent)	Aripiprazole (Percent)	Health control group (Percent)	Chi-Square
Male	75.0	45.0	30.0	35.0	0.020 (Cramer’s V = 0.350)
Female	25.0	55.0	70.0	65.0
Age	Risperidone (Mean ± SD)	Clozapine (Mean ± SD)	Aripiprazole (Mean ± SD)	Health control group (Mean ± SD)	ANOVA	pa	pb	pc	pd	pe	pf
Age	43.70 ± 7.61	45.65 ± 12.24	40.60 ± 12.77	44.50 ± 9.83	0.489	0.941	0.801	0.995	0.456	0.987	0.665

The Shapiro-Wilk normality test was used to check the normality of the data distribution. For all four groups of data, we conclude that the data follow the normal distribution. Since the data follow a normal distribution, for age in relation to the defined groups of subjects we use a parametric test, a one-factor ANOVA for different groups with subsequent tests. Using the chi-square test for independence, we found that the gender of the respondents and the group to which they belong (the drug they use) are dependent characteristics (p < 0.05). To assess the “strength” of this result, we calculated the magnitude of the impact of using Cramer’s V coefficient, which is 0.350 and indicates a strong impact.

p^a: Risperidone vs. Clozapine group; p^b: Risperidone vs. Aripiprazole group; p^c: Risperidone vs. health control group; p^d: Clozapine vs. Aripiprazole group; p^e: Clozapine vs. health control group; p^f: Aripiprazole vs. health control group.